Clinical picture in one paragraph: 63F, postmenopausal, with bilateral 1st CMC osteoarthritis, multiple right toe pain (cause not specified), and severe left thigh sciatica from L-S spine (the dominant complaint in April 2026). A 10-day medication course (Aceclofenac + Paracetamol + Chlorzoxazone + Pregabalin 75 + Nortriptyline 10 + Methylcobalamin 1500 + Rabeprazole + Domperidone + Vitamin D3 oral + Arachitol 300,000 IU IM) was completed on/around 28 April 2026. Pain has substantially improved since. She is currently off all prescription medication. Round 2 labs (19 May 2026) ruled out Hashimoto's thyroiditis (Anti-TPO and Anti-Tg negative), rheumatoid arthritis (Anti-CCP 0.90), and insulin resistance (HOMA-IR 0.89). B12, TSH, CRP, Calcium, and Fasting Glucose have all normalized. Vitamin D corrected and sufficient. We are seeking your assessment of the residual findings and the path forward without lifelong painkillers.
Key Lab Trajectory (Nov 2025 → May 2026)
| Marker |
Nov 2025 |
May 2026 |
Reference |
Status |
| TSH (µIU/mL) | 7.275 | 4.526 | 0.55–4.78 | Normalized |
| Vitamin B12 (pg/mL) | 170 | 361 | 211–911 | Corrected |
| Vitamin D, 25-OH (ng/mL) | 40.2 | 42.9 | ≥30 | Sufficient |
| Calcium, serum (mg/dL) | 8.3 | 8.9 | 8.7–10.4 | Normalized |
| Fasting Glucose (mg/dL) | 103 | 95 | 70–99 | Normalized |
| CRP, Quantitative (mg/L) | 5.30 | 2.30 | 0–3.3 | Normalized |
| HbA1c (%) | 6.2 | 6.3 | <5.6 | Pre-diabetic |
| Homocysteine (µmol/L) | 18.66 | 17.19 | 3.7–13.9 | Still elevated |
| HDL (mg/dL) | 34 | 40 | ≥50 | Low; improving |
| Triglycerides (mg/dL) | 124 | 168 | <150 | Borderline-high |
| Potassium (mEq/L) | 4.48 | 3.62 | 3.5–5.1 | Low-normal |
| AST / ALT (U/L) | 30 / 29 | 36 / 37 | <34 / 10–49 | AST mildly up |
| PTH, Intact (pg/mL) | — | 78.60 | 18.4–80.1 | Upper limit |
| Lp(a) (mg/dL) | 42.90 | — | <30 | Genetic; elevated |
| Anti-TPO / Anti-Tg (IU/mL) | — | <3 / <3 | <5.61 / <4.11 | Negative |
| Anti-CCP (U/mL) | — | 0.90 | <5.0 | Negative |
| HOMA-IR | — | 0.89 | <2.5 | Optimal |
| Magnesium (mg/dL) | — | 2.07 | 1.30–2.70 | Normal |
Medications
Currently off all prescription medication since ~28 April 2026 (~3 weeks at time of blood draw).
| Brand | Composition | Status |
|---|
| KEDAC-CP+ | Aceclofenac 100 + Paracetamol 500 + Chlorzoxazone 250 | Completed 10-day course |
| YOPREG-NM | Pregabalin 75 + Nortriptyline 10 + Methylcobalamin 1500 | Completed 10-day course |
| ROWET-DSR | Rabeprazole 20 + Domperidone 30 | Completed 10-day course |
| D3 ADEN + Inj. Arachitol 3L | Cholecalciferol oral + 300,000 IU IM loading | Completed loading |
| A2L | Multivitamin | Completed |
| T. Castrou | composition unverified | Completed 5-day course |
| K2-GOOD (separately acquired) | Calcitriol 0.25 mcg + Calcium carbonate 625 mg + K2-7 22.5 mcg + Boron + Zinc | Coordination with prescriber needed |
Active Concerns (Watch List)
- Homocysteine 17.19 µmol/L — still elevated despite B12 normalization (361). Suggests an unresolved co-factor issue (folate active form, B6, or methylation polymorphism). Independent risk factor for cardiovascular events and fracture; possibly relevant to her vascular and bone health.
- Potassium 3.62 mEq/L — low-normal. Drawn 3 weeks after stopping medications, so reflects her actual state. Cause not investigated (diet, possible diuretic effect, magnesium-related).
- AST 36 U/L (ALT 37) — mildly elevated. Possibly residual from Chlorzoxazone or Aceclofenac exposure; could also reflect non-alcoholic fatty liver in pre-diabetic state. Repeat LFT recommended at 4–6 weeks.
- Triglycerides 168 mg/dL — borderline-high (up from 124). Drawn off Pregabalin so not a drug effect. Combined with low HDL and elevated Lp(a), reflects atherogenic dyslipidemia pattern.
- PTH 78.60 pg/mL (upper limit of normal) — within reference but worth context given prior Vitamin D deficiency history. Suggests checking 24-hr urinary calcium and repeat PTH.
- Lp(a) 42.90 mg/dL — genetic, largely unmodifiable; drives aggressive management of other cardiovascular risk factors.
- IgE Total — was 299 IU/mL in Nov 2025 (rising from 257). Not retested in Round 2 (possible lab omission). Stool exam clean (no parasites).
- Weight not tracked — no baseline. Starting weekly weighing.
Questions for the Doctor
- Homocysteine workup: Should we order RBC folate and Plasma Vitamin B6 (P5P) before considering further intervention? Is MTHFR genotyping clinically warranted here, or is a trial of methylated B-complex (with B6 capped to avoid neuropathy risk) more appropriate?
- Bone health: Given prior Vitamin D deficiency, postmenopausal status, and PTH at upper limit, would you recommend a DEXA scan with FRAX risk assessment now?
- Hand OA: Bilateral 1st CMC OA. Would you support a thumb CMC orthosis (per ACR strong recommendation), hand therapy referral, and topical diclofenac 1% gel for breakthrough pain, in lieu of oral NSAIDs?
- Multiple toe pain: Not yet diagnostically characterized. Would you want a focused exam plus possible foot X-ray to differentiate MTP OA, gout/pseudogout, neuropathic, or other?
- Sciatica: Resolved with the recent course. MRI of L-S spine indicated now as a precaution, or watch-and-wait with red-flag monitoring? What red flags should we watch for (e.g., new weakness, bladder/bowel changes, gait change)?
- K2-GOOD (Calcitriol): Whose prescription, what indication? It overlaps with the recent Cholecalciferol loading dose. Should it continue, pause, or stop?
- T. Castrou: Composition could not be verified by us. Could you confirm what it was for so we know whether it is needed in future?
- AST elevation: Repeat LFT (ALT/GGT/CK) in 4–6 weeks, or sooner? Fatty liver screen recommended given pre-diabetes and triglyceride drift?
- Pre-diabetes: HbA1c 6.3% with HOMA-IR 0.89 suggests post-prandial spike pattern. Are post-meal walks + carb redistribution sufficient, or would you want a structured CGM trial?
- IgE retest: Order now (was missed in Round 2), or only if she develops allergic symptoms?
Interventions Under Consideration (Pending Your Sign-off)
Evidence-based first-line
- Thumb CMC orthosis for 1st CMC OA (ACR strongly recommends)
- Hand / occupational therapy referral
- Topical diclofenac 1% gel for breakthrough joint pain
- Resistance training 2–3×/week for postmenopausal bone preservation and sarcopenia prevention
- Tai Chi or yoga 3×/week for balance, falls prevention
- Post-meal walking (5–10 min after each meal) for post-prandial glucose
- Mediterranean-style Indian diet with reduced refined carbohydrates
- Hydration audit (~2.5 L/day water)
- Dietary potassium emphasis (bananas, coconut water, dates, leafy greens)
- Weekly weight tracking (no baseline yet)
- Sleep hygiene + STOP-BANG sleep apnea screen
- Dental + periodontal evaluation (inflammation source)
Supplements (max 3–4, after your approval)
- Methylated B-complex (5-MTHF + methylcobalamin + P5P B6, B6 capped at safe dose) — for elevated homocysteine
- Vitamin K2 (MK-7) 180 mcg/day — bone density support (modest evidence; dose at studied lower range)
- Omega-3 (EPA+DHA) ~1–2 g/day — modest HDL improvement, anti-inflammatory; caution if any future antiplatelet/NSAID use
- Curcumin (bioavailable form) — only after LFT confirms AST normalization; otherwise hold
Deferred until your sign-off: UC-II collagen, Boswellia, SAMe, glucosamine/chondroitin, calcium supplement, magnesium supplement, selenium. (We had drafted a larger stack; adversarial review recommended cutting it down.)
3-Month Follow-Up (~ August 2026)
Planned retest panel: HbA1c, FBS, TSH, Free T4, Vitamin B12, Homocysteine, Vitamin D, Calcium, Phosphorus, PTH, Lipid Profile, LFT (AST/ALT/GGT), Potassium + electrolytes, CBC + hs-CRP. Plus DEXA if not done sooner, and any additional tests you recommend.
Source Documents